## $\tilde{D} \otimes \tilde{D} \gg \tilde{D}_{\tilde{s}} \tilde{N} \cdot \tilde{D} \boxtimes \tilde{D} \mu \tilde{D}' \tilde{D}^{3/4} \tilde{N}, \tilde{D}^{o} \tilde{D}_{\tilde{s}} \tilde{D}^{1/2} \tilde{D}^{o}$

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4579647/publications.pdf

Version: 2024-02-01

3311381 2917675 3 3 1 2 citations h-index g-index papers 3 3 3 2 docs citations times ranked all docs citing authors

#	ARTICLE	IF	CITATIONS
1	PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN. Atherothrombosis, 2020, , 46-54.	0.3	1
2	Characteristics of patients with active cancer and venous thromboembolic complications receiving a chemotherapy treatment cycle (according to the â€real-life' clinical practice of Publicly Funded Health) Tj ET	Qq0,00 r	gBŢ /Overlock
	Atherothrombosis, 2022, 11, 44-54.		
3	Markers of hemostasis activation and endothelial damage in patients with active cancer. Atherothrombosis, 2022, 12, 127-137.	0.3	1